Compare Natera Inc. Common Stock (NTRA) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs SpaceX — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while SpaceX trades at $147.97 (market cap $2.07T). The key difference: SpaceX is far larger — about 36.3× Natera Inc. Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, SpaceX nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and SpaceX for 42 Days on average.
| NTRA | SPCX | |
|---|---|---|
Market Cap | $57.03B | $2.07T |
Volume | 1,131,157 | 67,600,447 |
Sector | Health | Industrials |
52-Week High | $425.64 | $202.09 |
52-Week Low | $179.42 | $108.27 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $56.18B | $2.00T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SpaceX (SPCX) trades at $156.54, down 4.21% amid broader market weakness despite recent operational successes. Technical indicators show a bullish trend with strong institutional buying support. The company maintains robust revenue growth projections ($23B for 2026) but faces profitability challenges with negative net margins (-35.66%) and elevated valuations (P/S 72.26). Recent news highlights Starlink's expansion into wireless markets while geopolitical tensions create operational complexities.
Long-term growth prospects remain compelling given SpaceX's dominant market position and Starlink expansion, though current valuations require substantial future execution. Key risks include execution on massive capital expenditures, competitive pressures in satellite communications, and geopolitical sensitivities. Analyst consensus remains strongly bullish with a $211.43 price target representing 35% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
